We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Attenuated Inflammatory Response in Laparoscopic Colon Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01419431
First Posted: August 18, 2011
Last Update Posted: December 16, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dag T Førland, Oslo University Hospital
  Purpose
Pro-inflammatory responses following laparoscopic surgery.

Condition Intervention
Regulation of Inflammatory Response Procedure: Laparoscopic resection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery

Further study details as provided by Dag T Førland, Oslo University Hospital:

Primary Outcome Measures:
  • Inflammatory values for laparoscopic resection for colon cancer. [ Time Frame: 3 days ]
    Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer.


Estimated Enrollment: 20
Study Start Date: January 2007
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Colon cancer patients
Laparoscopic resection
Procedure: Laparoscopic resection
Inflammatory response in laparoscopic surgery
Other Name: Colon cancer

Detailed Description:
Blood samples from 20 patient with colon cancer collected before and in 3 days following laparoscopic surgery. Analyzed for inflammatory cytokines and corresponding SOCS3 mRNA.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Colon cancer stage I-III
Criteria

Inclusion Criteria:Colon cancer stage I-III -

Exclusion Criteria:Colon cancer stage IV

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419431


Locations
Norway
Oslo University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Dag T. Førland, MD OUS
  More Information

Responsible Party: Dag T Førland, MD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01419431     History of Changes
Other Study ID Numbers: SOCS3 mRNA
SOCS-3-202008 ( Other Grant/Funding Number: OUS-SOCS3 )
First Submitted: July 18, 2011
First Posted: August 18, 2011
Last Update Posted: December 16, 2011
Last Verified: December 2011

Keywords provided by Dag T Førland, Oslo University Hospital:
Colon cancer